Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S VanderBrug Medendorp

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Ophthalmology|December 31, 1997
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trialH Lewis, S VanderBrug Medendorp
American Journal of Preventive Medicine|September 1, 1991
Screening for the detection of coronary artery disease by using the exercise tolerance test in a preventive medicine populationR L Dunn, R N Matzen, S VanderBrug-Medendorp
Clinical Pediatrics|May 1, 1995
The Ohio Bicycle Injury StudyS J Ashbaugh, M L Macknin, S VanderBrug Medendorp
Chest|November 1, 1988
Survival experience following Nd:YAG laser photoresection for primary bronchogenic carcinomaS J Desai, A C Mehta, S VanderBrug Medendorp, et al.
Neurology|November 1, 1996
Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIsD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.
The Journal of Urology|June 1, 1990
Intracavernous injection therapy: analysis of results and complicationsM M Lakin, D K Montague, S VanderBrug Medendorp, et al.
Cleveland Clinic Journal of Medicine|November 1, 1988
Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinomaD B Seifer, A W Kennedy, K D Webster, et al.
Annals of Neurology|October 1, 1996
Interferon beta induces interleukin-10 expression: relevance to multiple sclerosisR A Rudick, R M Ransohoff, R Peppler, et al.
The Journal of Urology|February 1, 1989
Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancerD P Wood, J E Montie, J E Pontes, et al.
Annals of Neurology|January 1, 1995
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Ophthalmology|December 31, 1997
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trialH Lewis, S VanderBrug Medendorp
American Journal of Preventive Medicine|September 1, 1991
Screening for the detection of coronary artery disease by using the exercise tolerance test in a preventive medicine populationR L Dunn, R N Matzen, S VanderBrug-Medendorp
Clinical Pediatrics|May 1, 1995
The Ohio Bicycle Injury StudyS J Ashbaugh, M L Macknin, S VanderBrug Medendorp
Chest|November 1, 1988
Survival experience following Nd:YAG laser photoresection for primary bronchogenic carcinomaS J Desai, A C Mehta, S VanderBrug Medendorp, et al.
Neurology|November 1, 1996
Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIsD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.
The Journal of Urology|June 1, 1990
Intracavernous injection therapy: analysis of results and complicationsM M Lakin, D K Montague, S VanderBrug Medendorp, et al.
Cleveland Clinic Journal of Medicine|November 1, 1988
Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinomaD B Seifer, A W Kennedy, K D Webster, et al.
Annals of Neurology|October 1, 1996
Interferon beta induces interleukin-10 expression: relevance to multiple sclerosisR A Rudick, R M Ransohoff, R Peppler, et al.
The Journal of Urology|February 1, 1989
Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancerD P Wood, J E Montie, J E Pontes, et al.
Annals of Neurology|January 1, 1995
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.
Pageof 2